New drug HU6 targets fatty liver disease in Mid-Stage trial
Disease control
Recruiting now
This study tests a new drug called HU6 for people with MASH, a serious fatty liver disease. About 180 adults aged 30 and older will receive either HU6 or a placebo to see if the drug safely reduces liver fat. The trial lasts 26 weeks and focuses on safety and how well the drug wo…
Phase: PHASE2 • Sponsor: Rivus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC